Birchview Capital’s Bright Minds Biosciences DRUG Stock Holding History

Birchview Capital’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$767K	Buy	+15,400	New	+$1.09M	0.44%	47

Other funds holding DRUG

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Birchview Capital's DRUG Position: Q3 2026 in Review

Birchview Capital opened a new position in Bright Minds Biosciences (DRUG) in Q3 2026: 15,400 shares worth $767K. The stake represents 0.44% of the portfolio and ranks #47 among its holdings.

58 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

Birchview Capital held 15,400 shares of Bright Minds Biosciences worth $767K as of Q3 2026.
Bright Minds Biosciences was a new Birchview Capital position in Q3 2026.
Bright Minds Biosciences made up 0.44% of Birchview Capital's portfolio in Q3 2026, its #47 holding.
58 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Birchview Capital's 13F filing for Q3 2026, filed 13 Nov 2026.